Aquestive Therapeutics, Inc.
AQST
$4.06
$0.041.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.02M | 12.81M | 10.00M | 8.72M | 11.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.02M | 12.81M | 10.00M | 8.72M | 11.87M |
| Cost of Revenue | 5.84M | 4.51M | 4.56M | 3.65M | 4.52M |
| Gross Profit | 7.18M | 8.30M | 5.44M | 5.07M | 7.35M |
| SG&A Expenses | 32.82M | 15.25M | 12.71M | 19.07M | 16.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.85M | 24.29M | 21.37M | 28.09M | 25.45M |
| Operating Income | -28.84M | -11.48M | -11.37M | -19.37M | -13.58M |
| Income Before Tax | -31.86M | -15.45M | -13.55M | -22.93M | -17.07M |
| Income Tax Expenses | -- | -- | -- | -- | -14.00K |
| Earnings from Continuing Operations | -31.86M | -15.45M | -13.55M | -22.93M | -17.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.86M | -15.45M | -13.55M | -22.93M | -17.06M |
| EBIT | -28.84M | -11.48M | -11.37M | -19.37M | -13.58M |
| EBITDA | -28.68M | -11.34M | -11.23M | -19.23M | -13.41M |
| EPS Basic | -0.26 | -0.14 | -0.14 | -0.24 | -0.19 |
| Normalized Basic EPS | -0.16 | -0.09 | -0.09 | -0.15 | -0.11 |
| EPS Diluted | -0.26 | -0.14 | -0.14 | -0.24 | -0.19 |
| Normalized Diluted EPS | -0.16 | -0.09 | -0.09 | -0.15 | -0.11 |
| Average Basic Shares Outstanding | 121.97M | 110.58M | 99.33M | 95.50M | 91.20M |
| Average Diluted Shares Outstanding | 121.97M | 110.58M | 99.33M | 95.50M | 91.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |